Source link : https://yourblogdomain.com/2026/03/24/avapritinibs-effect-durable-in-indolent-systemic-mastocytosis/
Source link : https://newshealth.biz/health-news/avapritinibs-effect-durable-in-indolent-systemic-mastocytosis/ Long-term data from the PIONEER trial, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, support the durability of response with the KIT inhibitor avapritinib (Ayvakit) for indolent systemic mastocytosis. In this exclusive MedPage Today video, Tsewang Tashi, MD, of the University of Utah Huntsman Cancer Institute […]
—-
Author : yourblogdomain
Publish date : 2026-03-24 19:06:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8